JMP Securities Maintains Market Outperform on Rallybio, Lowers Price Target to $16
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Rallybio (NASDAQ:RLYB) but lowers the price target from $26 to $16.
June 26, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Rallybio (NASDAQ:RLYB) but lowers the price target from $26 to $16.
The news of JMP Securities maintaining a Market Outperform rating on Rallybio is positive for the stock. However, the lowering of the price target from $26 to $16 may create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100